Skip to main content

Year: 2025

Alpha Modus Holdings, Inc. (NASDAQ: AMOD) To Launch AlphaCash, Appoints Puneet “Pete” Vij as VP of Technology to Lead Nationwide Rollout

New subsidiary Alpha Modus Financial Services to drive multi-year national deployment of AI-powered financial kiosks in partnership with Uptiq CORNELIUS, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (NASDAQ: AMOD) today announced the appointment of Puneet “Pete” Vij as Vice President of Technology, where he will oversee the company’s national rollout of AlphaCash, its proprietary network of next-generation financial service kiosks. The rollout will be managed under Alpha Modus Financial Services, a newly formed subsidiary of Alpha Modus Holdings dedicated to advancing financial inclusion through AI-driven retail infrastructure.This leadership appointment follows the company’s decision to transition from an external rollout partner model to an internalized deployment strategy, enabling full ownership, scalability,...

Continue reading

Sound Group Collaborates With HKUST(GZ) To Cultivate AI Innovation Talent

SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) — Sound Group Inc. (“Sound Group” or the “Company”) (NASDAQ: SOGP), a global AI-powered audio company, today announced that one of its subsidiaries has officially donated to establish the “HKUST(GZ) Information Hub – LIZHI Innovation Talent Scholarship” (the “LIZHI Innovation Talent Scholarship”) at The Hong Kong University of Science and Technology (Guangzhou). The scholarship will provide recipients with opportunities to participate in AI and data science–related internships and innovation projects. Through this initiative, Sound Group aims to build a co-creation platform between enterprises and outstanding young talents, promoting deeper integration between industry, academia, and research. Hosted by the HKUST(GZ) Information Hub, the collaboration and LIZHI...

Continue reading

Form 8.5 (EPT/RI)- Amendment of Inspecs Group PLC

FORM 8.5 (EPT/RI) Amendment 2(a) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Inspecs Group plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor to H2 Equity Partners Ltd(d)        Date dealing undertaken: 23rd October 2025(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible...

Continue reading

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia CHATHAM, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated commercial biotechnology company presented data on Tonmya™, which was investigated as TNX-102 SL, at the 2025 American College of Rheumatology (ACR) Convergence, held October 24–29, 2025, in Chicago, Illinois. A copy of the Company’s presentation, titled “TNX-102 SL, Cyclobenzaprine HCl Sublingual...

Continue reading

Carbon Streaming Announces Appointment of Jonathan Rubenstein as Expert Consultant

TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) today announced that it has appointed Jonathan Rubenstein, LLB, as expert consultant to the Company to provide oversight, guidance and strategic direction to the Company for significant litigation. Mr. Rubenstein has decades of experience in the mining sector having transitioned into mining from a successful 18 year career as a lawyer in private practice. As a senior officer or director, he successfully directed and negotiated a number of acquisitions, 8 takeover transactions, (two of which were contested) and dozens of commercial, contractual and regulatory matters. He served as a board member of over 10 significant mining companies, including Canico Resource Corp., Cumberland Resources...

Continue reading

Electra Advances Idaho Cobalt-Copper Assets as Cornerstone of America’s Critical Minerals Independence

Renewed exploration focus supports domestic mining strategy for Electra’s fully financed North American cobalt refinery TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) has launched a new program to advance mineral deposit modelling and feedstock integration at its Iron Creek cobalt-copper project in Idaho, supporting U.S. efforts to onshore critical mineral production and reduce dependence on foreign supply chains. With financing for its North American cobalt refinery now completed and construction scheduled to resume, Electra is leveraging its strengthened balance sheet to advance its next phase of growth, onshoring not only mineral processing but also mining capabilities to meet rising U.S. demand for critical minerals. “America needs cobalt,...

Continue reading

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

– All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies – Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p

Continue reading

Currency Exchange International Announces Adoption of Shareholder Rights Plan

TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Currency Exchange International, Corp. (the “Group” or “CXI”) (TSX: CXI; OTCQX: CURN), announced today that its board of directors (the “Board”) has unanimously approved the adoption of a “new generation” shareholder rights plan (the “Rights Plan”) pursuant to a shareholder rights plan agreement entered into with Computershare Trust Company of Canada, as rights agent, dated October 27, 2025 (the “Effective Date”). In alignment with good governance practices, the Rights Plan is being adopted to help ensure that all shareholders of the Company are treated fairly and equally in the event of any unsolicited take-over bid or other acquisition of control of the Company (including by way of a “creeping take-over bid”), allowing the Board time and opportunity to identify, solicit and develop...

Continue reading

First Northwest Bancorp Announces Third Quarter 2025 Results

PORT ANGELES, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) — First Northwest Bancorp (Nasdaq: FNWB) (“First Northwest” or the “Company”), the holding company for First Fed Bank (“First Fed” or the “Bank”), today reported net income of $802,000 for the third quarter of 2025, compared to net income of $3.7 million for the second quarter of 2025 and a net loss of $2.0 million for the third quarter of 2024. Basic and diluted income per share were $0.09 for the third quarter of 2025, compared to basic and diluted income per share of $0.42 for the second quarter of 2025 and basic and diluted loss per share of $0.23 for the third quarter of 2024.  Management Outlook:“With over a century of history behind First Fed, I’m committed to honoring that legacy by continuing to deliver long-term...

Continue reading

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share. The gross proceeds to Nurix from the offering were $250.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix. “The successful completion of this offering not only allows Nurix to accelerate our implementation of pivotal trials in chronic lymphocytic leukemia (CLL), but it also enables us to move more decisively to explore the use of bexobrutideg...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.